SCHEMBL1716070

SCHEMBL1716070

N#CC1(Nc2ccc(C(=O)O)cc2)CCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.60
GAA P10253 1/20 0.51
ALDH1A1 P00352 4/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CTSL P07711 2/20 0.40
NPC1 O15118 1/20 0.40
TSHR P16473 2/20 0.39
TP53 P04637 1/20 0.39
ATM Q13315 1/20 0.38
CYP26A1 O43174 2/20 0.38
CYP3A4 P08684 2/20 0.38
RARA P10276 2/20 0.38
RARB P10826 2/20 0.38
RARG P13631 2/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31655436 0.83 CYP1A2 (0.55) CYP1A2GAAALDH1A1RAB9AKDM4E
SCHEMBL1715165 0.81 CYP1A2 (0.57) CYP1A2GAAKDM4EMEN1KMT2A
SCHEMBL2126554 0.80 CYP1A2 (0.68) CYP1A2GAAALDH1A1KDM4EMEN1
SCHEMBL20340379 0.79 GAA (0.65) CYP1A2GAAALDH1A1RAB9AKDM4E
SCHEMBL1715829 0.78 CYP1A2 (0.53) CYP1A2GAASMN1; SMN2EPHX2
SCHEMBL1715467 0.77 CYP1A2 (0.80) CYP1A2GAAALDH1A1SMN1; SMN2CTSL
SCHEMBL12456441 0.76 CYP1A2 (0.68) CYP1A2GAASMN1; SMN2TSHRPDE4A
SCHEMBL28036437 0.76 GAA (0.61) CYP1A2GAAALDH1A1RAB9AKDM4E
SCHEMBL548039 0.76 CYP1A2 (0.50) CYP1A2GAAALDH1A1SMN1; SMN2TSHR
SCHEMBL19128446 0.76 CYP1A2 (0.47) CYP1A2GAAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333385-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-30 US disclosed
US-20240132452-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-04-25 US disclosed
CN-116003328-A Diaryl hydantoin compounds 加利福尼亚大学董事会 2023-04-25 CN disclosed
US-20230109968-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-13 US disclosed
CN-110003114-B Diarylhydantoin compounds 加利福尼亚大学董事会 2023-01-17 CN disclosed
EP-3970721-A1 DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-03-23 EP disclosed
US-20210238145-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-05 US disclosed
US-20200079741-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-03-12 US disclosed
CN-110003114-A Diarylhydantoin compounds 加利福尼亚大学董事会 2019-07-12 CN disclosed
US-20190210974-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-07-11 US disclosed
EP-2561871-A1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer The Regents of The University of California (US) 2013-02-27 EP disclosed
US-20130034501-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-02-07 US disclosed
US-20120295944-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-22 US disclosed
US-8183274-B2 Treatment of hyperproliferative disorders with diarylhydantoin compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-22 US disclosed
EP-2444085-A1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer The Regents of The University of California (US) 2012-04-25 EP disclosed
EP-1893196-B1 DIARYLHYDANTOIN COMPOUND UNIV CALIFORNIA (US) 2012-01-18 EP disclosed
US-20100210665-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-08-19 US disclosed
US-20100172975-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-08 US disclosed
US-7709517-B2 N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-05-04 US disclosed
US-20070004753-A1 N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132452-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885
US-20120295944-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS CDK4, CCNH, VHL CYP1A2 3479/4885GAA 4448/4885ALDH1A1 1580/4885
US-20070004753-A1 N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer AR, BRDT, GNRHR CYP1A2 2341/4885GAA 4869/4885ALDH1A1 1572/4885
US-20100172975-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS CDK4, CCNH, VHL CYP1A2 3479/4885GAA 4448/4885ALDH1A1 1580/4885
US-20250333385-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885
US-20190210974-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885
US-20200079741-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885
US-20130034501-A1 DIARYLHYDANTOIN COMPOUNDS FAP, LEF1, LPXN CYP1A2 668/4885GAA 3990/4885ALDH1A1 550/4885
US-20230109968-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885
US-20210238145-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885
US-20100210665-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG CYP1A2 1177/4885GAA 4854/4885ALDH1A1 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.